Insilico

MISSION Our mission is to extend healthy productive longevity by transforming drug discovery and development with artificial intelligence software, significantly reducing the time and cost to bring life-saving medications to patients. Working with pharmaceutical and academic partners, we seek to accelerate and improve drug research and development efforts with our end-to-end, validated Pharma.AI platform and experienced team of scientists. Our goal is to facilitate a precision medicine future while developing an internal pipeline in core therapeutic areas including fibrosis, oncology, immunology and central nervous system disorders. We are an end-to-end, artificial intelligence-driven pharma-technology company with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary platform across biology, chemistry and clinical development. Our Pharma.AI platform has the potential to rapidly bring novel breakthrough medicines to patients while decreasing costs and increasing probabilities of success. --- Insilico Medicine is an artificial intelligence company headquartered in Hong Kong, with R&D and management resources in the USA, China, Canada, UAE, Belgium, UK, and Taiwan sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research. Insilico Medicine pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. To main content EN — 简 — FR MAINABOUT PHARMA.AI PIPELINENEWS & MEDIA CAREERSDOCUTHON ARTIFICIAL INTELLIGENCE FOR EVERY STEP OF PHARMACEUTICAL RESEARCH AND DEVELOPMENT Integrated, Universal & Experimentally-Validated Enroll for FreeDISEASE MODELING AND TARGET DISCOVERY COURSE OUR MISSION IS TO ACCELERATE DRUG DISCOVERY AND DRUG DEVELOPMENT We are an end-to-end, artificial intelligence-driven pharma-technology company with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary platform across biology, chemistry and clinical development. Our Pharma.AI platform has the potential to rapidly bring novel breakthrough medicines to patients while decreasing costs and increasing probabilities of success. PandaOmicsChemistry42InClinicoEnabling multi-omics target discovery and deep biology analysis engine to considerably reduce required time from several months to the span of just a few clicksFind novel lead-like molecules in a week through this automated, machine learning de-novo drug design and scalable engineering platformPredict clinical trials success rate, recognize the weak points in trial design, while adopting the best practices in the industryDiscover and Prioritize Generate Design and predict Novel TargetsNovel MoleculesClinical TrialsPHARMA.AIINTRODUCING FULLY-INTEGRATED DRUG DISCOVERY SOFTWARE SUITE Nobel Laureate Michael Levitt: How Early Protein Modeling Advanced to AI-Driven Drug Discovery with Insilico Medicine Stanford professor Michael Levitt, PhD, a member of Insilico Medicine's Scientific Advisory Board, won the Nobel Prize in Chemistry in 2013 for his groundbreaking work in protein structure and protein folding using computer modeling. In this lecture, Dr. Levitt describes how the work he began over 50 years ago has been vastly improved and expanded through the massive increase in computer speed and incredible advances in machine learning. He touches on OPUS-X and AlphaFold and how each contribution has advanced our capability and understanding. Now, says Dr. Levitt, Insilico Medicine is using AI to create an entirely new AI-driven drug discovery pipeline from A to Z. Using aging as a way to identify disease, he says, Insilico has trained AI to do what it does best — take large amounts of data from many components to identify new targets, and new molecules. “ Uncertainty is a good thing. By combining data with clever filtering we get certainty and options from uncertainty.' Dr. Levitt sees massive possibilities ahead. 'The protein-folding problem that was a very difficult problem for 50 years, and drug design, are all being dealt with in this global, all-encompassing way. And I am personally very, very optimistic.' Stanford professor Michael Levitt, PhD NEWS Insilico Medicine announces positive topline results of the New Zealand Phase 1 trial of INS018_055, an AI-designed drug for an AI-discovered target 10-JANUARY-2023 Read Insilico Medicine receives IND approval for novel AI-designed USP1 inhibitor for cancer 25 MAY 2023 Read Insilico Medicine founder and CEO Alex Zhavoronkov, Ph.D., presents on AI Drug Discovery for NIH National Institute on Drug Abuse 23 MAY 2023 Read Insilico Medicine-led study combines quantum computing and generative AI for drug discovery 19 MAY 2023 Read Insilico Medicine delivers preclinical candidate targeting ENPP1 for cancer immunotherapy and the treatment of rare disease using generative AI 18 MAY 2023 Read Insilico Medicine founder and CEO Alex Zhavoronkov, PhD, presents at Asia Summit on Global Health 16 MAY 2023 Read Insilico Medicine appoints Michael Bayewitch as VP, Business Development and Strategy 15 MAY 2023 Read Insilico Medicine founder and CEO to give keynote on disease modeling with AI at PEGS Boston 11 MAY 2023 Read AI drug discovery company Insilico Medicine offers free course on target identification 10 MAY 2023 Read Head of Insilico Medicine's Hong Kong Office to give keynote on AI drug discovery at HKUST Big Data Institute 4 MAY 2023 Read High school student researchers find new brain tumor drug targets using AI 2 MAY 2023 Read Insilico Medicine founder and CEO Alex Zhavoronkov, Ph.D., presents at LSX World Congress 28 APRIL 2023 Read Insilico Medicine successfully discovered potent, selective, and orally bioavailable small-molecule inhibitor of CDK8 using generative AI 12 APRIL 2023 Read Insilico Medicine presents four posters featuring AI-designed anti-cancer drugs at AACR 4 APRIL 2023 Read Using AI to address aging and disease: Insilico Medicine's Alex Zhavoronkov, PhD presents at the Geroscience Summit 3 APRIL 2023 Read Insilico Medicine featured in BBC-produced series on biotech breakthroughs 29 MARCH 2023 Read Insilico Medicine brings AI-powered 'ChatPandaGPT' to its target discovery platform 13 MARCH 2023 Read Generative AI for drug discovery expert Alex Zhavoronkov, Ph.D. presents at NextMed Health March 14 10 MARCH 2023 Read Insilico Medicine's Generative AI Pioneer Alex Zhavoronkov, PhD at Lab of the Future March 9 1 MARCH 2023 Read Insilico Medicine sends first generative AI-designed drug for COVID-19 and variants to clinic 23-FEBRUARY-2023 Read Tech journalist and filmmaker Amelia Martyn-Hemphill announced as Docuthon judge 21-FEBRUARY-2023 Read Emmy Award-winning filmmaker Oren Rosenfeld joins Insilico Medicine's Docuthon as judge 9-FEBRUARY-2023 Read Insilico Medicine receives FDA Orphan Drug Designation for generative AI discovered and designed drug for idiopathic pulmonary fibrosis 8-FEBRUARY-2023 Read New paper explores Insilico Medicine's generative AI drug design platform Chemistry42 7-FEBRUARY-2023 Read Insilico Medicine opens largest AI-powered biotechnology research center in the Middle East 1-FEBRUARY-2023 Read New study uses AlphaFold and AI to accelerate design of novel drug for liver cancer 19-JANUARY-2023 Read Insilico Medicine announces positive topline results of the New Zealand Phase 1 trial of INS018_055, an AI-designed drug for an AI-discovered target 10-JANUARY-2023 Read Insilico Medicine receives IND approval for novel AI-designed USP1 inhibitor for cancer 25 MAY 2023 Read Insilico Medicine founder and CEO Alex Zhavoronkov, Ph.D., presents on AI Drug Discovery for NIH National Institute on Drug Abuse 23 MAY 2023 Read Insilico Medicine-led study combines quantum computing and generative AI for drug discovery 19 MAY 2023 Read Insilico Medicine delivers preclinical candidate targeting ENPP1 for cancer immunotherapy and the treatment of rare disease using generative AI 18 MAY 2023 Read MEDIA COVERAGE 10 pioneering companies implementing AI in drug discovery, development and beyond May 2 Students use AI technology to find new brain tumor therapy targets — with a goal of fighting disease faster May 1 New AI 'can accurately spot cancer': Algorithm is better at identifying cancerous nodules than existing methods, study claims April 30 Read more Privacy Policy Cookies Policy MAIN Mission Pipeline Team Careers Contact us PHARMA.AI PandaOmics Generative Biologics Chemistry42 inClinico NEWS Blog Publications Media Coverage DOCUTHON HONG KONG Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong NEW YORK 345 Park Avenue South, 2nd Floor Suite 006 New York, NY 10010 MONTREAL 1250 René-Lévesque Ouest, Suite 3710, Montréal, Québec, Canada H3B 4W8 ABU DHABI Level 6, Unit 08, Block A, IRENA HQ Building Masdar City, Abu Dhabi United Arab Emirates